U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search Publications by: Illarion Turko (Fed)

Search Title, Abstract, Conference, Citation, Keyword or Author
Displaying 1 - 25 of 43

Mass spectrometry enumeration of filamentous M13 bacteriophage

July 2, 2019
Author(s)
Tingting Wang, Ai Nguyen, Linwen Zhang, Illarion Turko
In the last decade, filamentous M13 bacteriophage has emerged into numerous biotechnological applications as a promising nontoxic and self-assembling biomaterial with specific binding properties. This raises a question about its upscale production that

Assessment of extracellular vesicles purity using proteomic standards

September 26, 2017
Author(s)
Tingting Wang, Kyle Anderson, Illarion Turko
The increasing interest in extracellular vesicles (EVs) research is fueled by reports indicating their unique role in intercellular communication and potential connection to the development of common human diseases. The unique role assumes unique protein

Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum

February 11, 2017
Author(s)
Natalia Mast, Kyle Anderson, Joseph Lin, Yong Li, Illarion Turko, Curtis Tatsuoka, Ingemar Bjorkhem, Irina A. Pikuleva
Cytochrome P450 27A1 (CYP27A1 or sterol 27-hydroxylase) is a ubiquitous, multifunctional enzyme catalyzing regio- and stereo-specific hydroxylation of different sterols. In humans, complete CYP27A1 deficiency leads to cerebrotendinous xanthomatosis or

A new approach to quantification of mAb aggregates using peptide affinity probes

February 10, 2017
Author(s)
Crystal Cheung, Kyle Anderson, Pooja Patel, Keale Cade, Karen W. Phinney, Illarion Turko
Using mAbs as therapeutic molecules is complicated by the propensity of mAbs to aggregate at elevated concentrations, which can lead to a variety of adverse events in treatment. Here, we describe a proof-of-concept for new methodology to detect and

QUANTITY: An Isobaric Tag for Quantitative Glycomics

November 30, 2015
Author(s)
Shuang Yang, Meiyao Wang, Lijun Chen, Illarion Turko, Karen W. Phinney, Shuwei Li
We describe the design and synthesis of a novel set of iso-baric tags for quantitative glycan profiling, which will have broad applications in carbohydrate based biomarker dis-covery, therapeutic protein characterization, and vaccine development.

Quantification of Borrelia burgdorferi membrane proteins in human serum: a new concept for detection of bacterial infection

November 17, 2015
Author(s)
Sao F. Cheung, Kyle Anderson, Kenia Benitez, Mark J. Soloski, John N. Aucott, Karen W. Phinney, Illarion Turko
The low abundance of bacterial proteins in human serum upon infection imposes a challenge for the early proteomic detection of bacterial infection. To address this challenge, we propose to take advantage of detecting membrane proteins released from

QconCAT: Internal Standard for Protein Quantification

October 21, 2015
Author(s)
Kerry M. Bauer, Karen W. Phinney, Illarion V. Turko
Protein quantification based on stable-isotope labeling mass spectrometry (SIL-MS) involves adding known quantities of stable-isotope labeled internal standards into biological samples. The internal standards are analogous to analyte molecules and

Histone H3 Ser57 and Thr58 Phosphorylation in 5XFAD Mouse Brain

June 20, 2015
Author(s)
Kyle W. Anderson, Illarion V. Turko, Natalia Mast, Irina A. Pikuleva
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, yet it is poorly understood. Currently, there is no treatment to delay onset or slow progression of AD. Epigenetics of AD is a growing field that has gained interest due to the

Quantifying CD4 receptor protein in two human CD4+ lymphocyte preparations for quantitative flow cytometry

December 11, 2014
Author(s)
Meiyao M. Wang, Martin Misakian, Hua-Jun He, Peter Bajcsy, Jeffrey M. Davis, Kenneth D. Cole, Illarion Turko, Lili Wang, Fatima Abbasi
For quantitative flow cytometry, a biological cell reference material with a known biomarker expression level is needed to transform a linear arbitrary fluorescence intensity scale obtained with fluorescent microspheres to an antibody bound per cell (ABC)

Trends in QconCATs for targeted proteomics

May 1, 2014
Author(s)
Junjun J. Chen, Illarion Turko
Targeted proteomics has received much attention because of the highly-sensitive, quantitative detection of proteins and post-translational modifications (PTMs). Quantification by targeted proteomics relies on mass spectrometry and isotope-labeled internal

Structural Basis for Inactivation of Giardia lamblia Carbamate Kinase by Disulfiram

April 11, 2014
Author(s)
Andrey Galkin, Liudmila Kulakova, Kap Lim, Catherine Chen, Wei Zhang, Illarion Turko, Osnat Herzberg
Carbamate kinase from Giardia lamblia is an essential enzyme for the survival of the organism. The enzyme catalyzes the final step in the arginine dihydrolase pathway converting ADP and carbamoyl phosphate to ATP and carbamate. We previously reported that

Determining carbapenemase activity with 18O labeling and targeted mass spectrometry

October 16, 2013
Author(s)
Meiyao Wang, Yang Shen, Illarion Turko, Daniel Nelson, Shuwei Li
Carbapenems are broad spectrum antibiotics considered as last resort drugs to treat bacterial infections. Carbapenem-hydrolyzing β-lactamases (also called carbapenemases), however, can confer bacterial resistance and represent a serious health threat. Here

Pretreatment with Pyridoxamine Mitigates Isolevuglandinassociated Retinal Effects in Mice Exposed to Bright Light

October 11, 2013
Author(s)
Casey Charvet, Aicha Saadane, Meiyao M. Wang, Robert Salomon, Henri Brunengraber, Christine Curcio, Illarion Turko, Irina Pikuleva
The benefits of antioxidant therapy for treating age-related macular degeneration, a devastating retinal disease, are limited. Perhaps species other than reactive oxygen intermediates should be considered as therapeutic targets. These could be lipid